Navigation Links
Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients
Date:12/6/2009

rrow.

The new, Phase 1 clinical trial involved 23 patients who received bortezomib-based therapy (bortezomib, tacrolimus, and methotrexate) after reduced-intensity stem cell transplants from mismatched-unrelated donors. Three dosage levels of bortezomib were tested. In updated results on 35 bortezomib-based mismatched-unrelated patients reported at ASH, GVHD rates and extent of immune system reconstitution were compared with patients who had received sirolimus-based therapy (sirolimus, tacrolimus, and methotrexate) after transplants from matched-related donors, matched-unrelated donors, and mismatched-unrelated donors.

The results show that the bortezomib-based therapy was safe and had little toxicity. Transplanted stem cells took root, or "engrafted" reliably, and the rate of GVHD in the bortezomib-based mismatched-unrelated transplants was comparable to that in sirolimus-based matched-related transplants. Interestingly, immune cell reconstitution was significantly improved in the bortezomib-based patients in the early post-transplant period (3-6 months), compared with the sirolimus-based patients.

"Our results suggest that borezomib is a promising novel immunomodulatory agent in donor stem-cell transplantation," Koreth says. "A Phase 2 trial is now accruing patients to help determine its ultimate effectiveness."


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
2. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
3. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
4. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
5. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
6. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
7. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
8. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
9. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
10. New drug shows promise for those with clotting disorders: McMaster researcher
11. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 Volunteers from ... against drug abuse this week with drug education lectures, ... education booklet distribution in cities around the world. , ... U.S. National Institute on Drug Abuse, abuse of alcohol ... annually in crime, lost work, decreased productivity and healthcare. ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) investigation, Bernstein Liebhard LLP has been ... Food & Drug Administration’s (FDA) Obstetrics and ... explore ways to mitigate the cancer risks associated ... invasive gynecological surgeries. According to a report published ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The Europe Well ... market in Europe with analysis and revenue forecast. The well ... around $2.4 billion in 2013 to $3.4 billion by 2018, ... Browse through the TOC of the Europe Well Intervention Market ... This also provides a glimpse of the segmentation in the ...
(Date:7/11/2014)... July 11, 2014 Utilizing the Keller ... Dr. William Koenig, has topped a record number of ... has performed over 400 successful procedures without the occurrence ... is well known across the country for his expertise ... record has long been the foundation for numerous studies ...
(Date:7/11/2014)... 2014 (HealthDay News) -- In people with sex addiction, ... to that seen in drug addicts as they consume ... differences in brain activity between patients who have compulsive ... of drug addicts," study author Dr. Valerie Voon, of ... university news release. Voon,s research involved 19 men ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2
... activities encourage Americans to move more and eat smart, ... national,response to a recent report that again this year, ... America On the Move Foundation(R) (AOMF),and YMCA of the ... a national, month-long celebration highlighting the,benefits of healthy, active ...
... when parents took part in therapy , , TUESDAY, Sept. 4 ... the treatment of teens with bulimia, a new study has ... the percentage of teens able to abstain from the eating ... often been seen as part of the problem, rather than ...
... complete picture of color vision evolution has led Biodesign ... with one of the worlds most rare and bizarre-looking ... performed the first sweeping study of color vision in ... with a unique combination of physical features including extremely ...
... the University of Sheffield have developed a long-acting growth ... could mean that children and adults with growth hormone ... reducing the need for daily treatments. , Most ... require frequent injections as therapy. However, the new technology ...
... Analysis of data highlighted by the Trust for America,s Health 2007 Annual, ... day ... with TV/Video games., SOUTHHAMPTON, Hampshire, Sept. 4 Over ... per day glued to a screen, more,than 1 in 7 children are ...
... American Diabetes Association launches new name, image for ... to take greater action against deadly disease, ... than,2,000 Maryland residents will gather donations and prepare ... to Fight Diabetes." Formerly,known as America,s Walk for ...
Cached Medicine News:Health News:America On the Move and More Than 1,500 YMCAs Kick Off Steptember 2007 2Health News:America On the Move and More Than 1,500 YMCAs Kick Off Steptember 2007 3Health News:America On the Move and More Than 1,500 YMCAs Kick Off Steptember 2007 4Health News:Parental Involvement Key to Battling Bulima 2Health News:Parental Involvement Key to Battling Bulima 3Health News:The aye-ayes have it: The preservation of color vision in a creature of the night 2Health News:The aye-ayes have it: The preservation of color vision in a creature of the night 3Health News:Researchers develop long-lasting growth hormone 2Health News:Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach 2Health News:ADA Challenges Marylanders to 'Step Out to Fight Diabetes' Epidemic 2
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... Consecutive Quarterly Dividend -- ABBOTT PARK, Ill., Sept. 16 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Pa., Sept. 16 Olympus, a precision technology ... core business areas of Medical and Surgical Products, ... Instruments and Cameras and Audio Products, has announced ... Olympus Innovation Awards Program. The national program, executed ...
Cached Medicine Technology:Abbott Declares 347th Consecutive Quarterly Dividend 2Abbott Declares 347th Consecutive Quarterly Dividend 3Abbott Declares 347th Consecutive Quarterly Dividend 4Abbott Declares 347th Consecutive Quarterly Dividend 5Abbott Declares 347th Consecutive Quarterly Dividend 6Olympus Launches 2011 National Innovation Awards Program 2Olympus Launches 2011 National Innovation Awards Program 3Olympus Launches 2011 National Innovation Awards Program 4
Standard general retractor system. Fully-adjustable to maintain a low profile in any approach and any patient. Blades can be stacked on top of each other in the operative site....
These retractors are packaged singly ready for sterilization at your facility....
... Pipetman Concept is a revolutionary ... and flexibility in mind, Pipetman Concept ... direct pipette-to-PC connectionthe only one of ... used with Diamond Tips from Gilson, ...
... 3 - Vivid family system designed to ... cardiovascular performance, and offer an even wider ... and the OR. , ,From color flow ... connectivity, the new Vivid 3 offers a ...
Medicine Products: